Market News & Trends
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Indaptus Therapeutics, Inc. recently announced Dr. Michael Newman, Founder and Chief Scientific Officer, has published his groundbreaking research in the peer-reviewed journal, Frontiers in Immunology.…
Can-Fite Achieves Milestone With First Patient Dosing in Pancreatic Cancer Phase 2a Clinical Trial
Can-Fite BioPharma Ltd. recently announced the dosing of the first patient in the Phase 2a clinical trial in patients with advanced pancreatic adenocarcinoma (NCT06387342). “We…
CERo Therapeutics Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
CERo Therapeutics Holdings, Inc. recently announced the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in…
Transgene & NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine in Head & Neck Cancer
Transgene and NEC Corporation recently announced 24.1 month median follow-up data from the ongoing randomized Phase 1 trial of TG4050 in the adjuvant treatment of head…
Lonza’s Synaffix Collaborates With BigHat Biosciences on the Development of a Machine Learning-Designed ADC
Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced…
Adipo Therapeutics Presents Positive Study Results About Potential Obesity Treatment
Adipo Therapeutics LLC recently presented data from two studies at the annual meeting of The Obesity Society in San Antonio. The studies were designed to…
Tilray Medical Announces Positive Results From Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis
Tilray Medical, a division of Tilray Brands, Inc. recently announced the final results of a new scientific study their team has supported titled, Oral Cannabis…
Palisade Bio Announces First Subject Dosed in Phase 1 Study for Moderate-to-Severe Ulcerative Colitis Treatment
Palisade Bio, Inc. recently announced it dosed its first subject in its Phase 1 clinical study of PALI-2108, an orally administered PDE4 inhibitor prodrug that…
Palvella Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial for Microcystic Lymphatic Malformations Treatment
Palvella Therapeutics, Inc. recently announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the safety and…
Bespak & Orbia Fluor & Energy Materials Unite to Accelerate Transition to Climate-Friendly Inhalers
Bespak and Orbia Advance Corporation, S.A.B. de C.V. Fluor & Energy Materials recently announced a collaboration intended to accelerate the transition to climate-friendly inhalers utilising…
Lisata Therapeutics & Valo Therapeutics Announce Preclinical Research Collaboration
Lisata Therapeutics, Inc. and Valo Therapeutics Oy recently announce a preclinical research collaboration to investigate the benefits of combining Lisata's novel product candidate, certepetide, with…
SGS Expands Cutting-Edge Spray Drug Delivery Testing Capabilities in Belgium Health Science Laboratory
SGS has announced an expansion in its spray drug delivery testing capabilities at their laboratory in Wavre, Belgium. Utilizing the latest Malvern Spraytec system, SGS…
Rice Bioengineers Shed Light on Dosing Challenges for Cancer Immunotherapy
A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) ⎯ a potent immune-boosting protein that holds promise for…
Sonnet BioTherapeutics Announces Patent Covering a Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Candidates
Sonnet BioTherapeutics Holdings, Inc. recently announced the USPTO has issued US Patent No. 12,134,635 titled Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same, covering two…
Transgene & ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Transgene and ProBioGen recently announce they have entered into a license agreement for ProBioGen’s AGE1.CR.pIX suspension cell line. This partnership aims to add value by…
Nxera Pharma & Antiverse Enter Collaboration to Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
Nxera Pharma and Antiverse recently announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). The collaboration combines Antiverse’s generative…
PrognomiQ Announces $34-Million Financing to Advance Development of Early Detection Test for Lung Cancer With Multi-Omics Platform
PrognomiQ recently announced its Series D financing of $34 million led by Seer, Inc., with participation from a new, large, strategic investor in the Diagnostics…
Nouscom’s Off-the-Shelf Neoantigen Immunotherapy Continues to Elicit Potent & Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to "Intercept" Cancer
Nouscom recently announced further promising data from the fully enrolled Phase 1b/2 study evaluating NOUS-209 for its potential to "intercept" cancer in Lynch Syndrome (LS)…
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
MannKind Corporation recently announced the successful completion of its first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis (IPF).…
EMA Confirms Acceptance of Marketing Authorization Application for a Proposed Biosimilar to Simponi
Alvotech and Advanz Pharma recently announced the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05, Alvotech’s proposed biosimilar to Simponi (golimumab),…
